Navigation Links
CV Therapeutics Announces License Agreement for Ranexa(R) in Europe With Menarini Group
Date:9/12/2008

- Upfront, milestone payments and promotional investment totaling up to

$385 million plus royalties -

PALO ALTO, Calif., Sept. 12 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc. (Nasdaq: CVTX) announced today that it has entered into an agreement granting exclusive rights to Ranexa(R) (ranolazine prolonged release tablets) in Europe and other countries to the Menarini Group. Menarini, with its significant pan-European presence, makes the most physician calls for cardiovascular products and has the fourth largest pharmaceutical sales team for delivering medical information to physicians in Europe.

In total, the agreement grants rights to Menarini for Ranexa in 68 countries, including the 27 countries of the European Union (EU), the Commonwealth of Independent States, and select countries of Central and South America.

In the agreement, Menarini has committed to make an upfront payment of $70 million in consideration of the rights granted and in recognition of the R&D investments made by CV Therapeutics. In addition, Menarini will potentially make additional payments and investments totaling up to $315 million (based on the current currency exchange rate) for commercial and development milestones and promotional and detailing commitments. The commercial milestones are primarily linked to sales levels and the development milestones are linked to approval of Ranexa in Europe for certain additional indications that are jointly developed. The agreement provides mechanisms for the parties to collaborate and share the costs of joint development of Ranexa.

Menarini will be responsible for commercial activities and pursuing regulatory and pricing approvals. As part of the agreement, Menarini has com
'/>"/>

SOURCE CV Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Cell Therapeutics to Host Investor Day in Milan, Italy on Friday, October 3, 2008
2. Halozyme Therapeutics to Present at Upcoming Investor Conferences
3. Intarcia Therapeutics, Inc. Announces Appointment of Kenneth Luskey, M.D. as Vice President, Clinical Research
4. Halozyme Therapeutics Strengthens Management Team, Appoints Additional Experienced Executives
5. CV Therapeutics Initiates Phase 1 Clinical Trial of CVT-3619, a Novel Potential Treatment for Cardiometabolic Diseases
6. Amicus Therapeutics to Present at the 2008 BioCentury NewsMakers in the Biotech Industry Conference
7. Orexigen(R) Therapeutics to Present at Upcoming Investor Conferences
8. CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350
9. Nile Therapeutics to Present at BioCenturys NewsMakers in the Biotech Industry Conference
10. TorreyPines Therapeutics Receives NASDAQ Deficiency Notice
11. Cell Therapeutics, Inc. Announces Reverse Stock Split
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... SEATTLE , July 11, 2014  Researchers ... navigate three-dimensional images. The new technology, called Virtual ... of small structures like neurons and synapses using ... Finger,s unique technology makes 3D imaging studies orders ... resources at an unprecedented level across many areas ...
(Date:7/10/2014)... (PRWEB) July 10, 2014 Women ... have access to an additional family planning option. ... to contraception at all levels of the health ... formulation of a widely used contraceptive—Pfizer’s Depo-Provera® (depot ... Burkina Faso is the first of four African ...
(Date:7/10/2014)... (PRWEB) July 10, 2014 Deep ... Century Medicine Forum on ‘Commercialising Longevity Research’ and ... entrepreneurs to the London Bioscience Innovation Center for ... Foundation and Aging Analytics Ltd. The meeting highlighted ... in translational research for age-related disease, as well ...
(Date:7/10/2014)... Terascala, the industry leader in HPC ... former vice president of product management for Flexera Software, ... marketing. Terascala’s software when combined with leading compute and ... performance and most reliable solutions for processing big data. ... expansion and broaden its product portfolio. His leadership in ...
Breaking Biology Technology:Virtual Finger Enables Scientists To Navigate And Analyze 3D Images Of Complex Biological Structures 2Virtual Finger Enables Scientists To Navigate And Analyze 3D Images Of Complex Biological Structures 3Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 2Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 3Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 4Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 5Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 6DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 2DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 3DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 4DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 5DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 6Terascala Expands Executive Team 2Terascala Expands Executive Team 3
... 5 - Evoke Pharma, Inc., a privately-held specialty ... Phase 2b clinical trial to evaluate EVK-001 for the ... is a syndrome characterized by delayed emptying of the ... absence of mechanical obstruction. Diabetes is an important cause ...
... Study Published in the Journal of Rheumatology Examines ... Gout PatientsEAST BRUNSWICK, N.J., May 5 Savient ... today the print publication of the Savient-supported longitudinal ... gout (TFG). The objective of the study was ...
... Milestone Payment from GlaxoSmithKlineMOUNTAIN VIEW, Calif., May 5 ... identified an orally bioavailable small molecule antagonist of ... clinical development. The acceptance of the molecule ... milestone payment from the alliance with GlaxoSmithKline (NYSE: ...
Cached Biology Technology:Evoke Pharma, Inc. Initiates Phase 2b Metoclopramide Intranasal Trial (MINT) in Patients With Diabetic Gastroparesis 2Evoke Pharma, Inc. Initiates Phase 2b Metoclopramide Intranasal Trial (MINT) in Patients With Diabetic Gastroparesis 3Disability and Poor Quality of Life Associated With Treatment Failure Gout Patients 2Disability and Poor Quality of Life Associated With Treatment Failure Gout Patients 3Disability and Poor Quality of Life Associated With Treatment Failure Gout Patients 4ChemoCentryx Identifies Novel Small Molecule C5aR Antagonist 2ChemoCentryx Identifies Novel Small Molecule C5aR Antagonist 3ChemoCentryx Identifies Novel Small Molecule C5aR Antagonist 4
(Date:7/11/2014)... group members to reduce aggression and gain access to ... grooming activities shows a certain pattern across the day. ... Biology Letters . , Grooming between individuals in ... motives. To be groomed has hygienic benefits and is ... can provide access to infants, mating opportunities and high ...
(Date:7/11/2014)... explored two different ways that allow unprecedented experimental ... formation of oxygen molecules in photosynthesis. The two ... Nature Communications . , "The new knowledge ... water oxidation, which are key components for building ... solar energy in fuels like hydrogen, ethanol or ...
(Date:7/11/2014)... of kidney injury related to the use of hydroxyethyl ... HES molecules, according to a report in Anesthesia ... Research Society (IARS). , The "total mass of HES ... human renal proximal tubule cells (PTCs), concludes the laboratory ... Hospital Wrzburg, Austria. Other factorssuch as differences in ...
Breaking Biology News(10 mins):Baboons groom early in the day to get benefits later 2Molecular snapshots of oxygen formation in photosynthesis 2In lab studies, hydroxyethyl starch has direct harmful effects on kidney cells 2
... geology as in cancer research, the silver bullet theory always ... wrong. For geologists who study mass extinctions, the silver ... an asteroid is the prime suspect only in the most ... Bottjer. The cataclysm 65 million years ago wiped out the ...
... PORTLAND, Ore. The National Institutes of Health has ... American scientists led by Oregon Health & Science University ... biofuels technology from marine mollusks for development in the ... Philippine archipelago whose waters are inhabited by an estimated ...
... Based on its recent,analysis of the noninvasive ... with the 2008 North American Award for Technology,Innovation ... optics-based,stand-off iris recognition system., The innovative iris ... identify a subject,s iris at a stand-off,distance of ...
Cached Biology News:Extinction by asteroid a rarity 2Discovering drugs, biofuels in tropical seas 2Discovering drugs, biofuels in tropical seas 3Discovering drugs, biofuels in tropical seas 4Frost & Sullivan Recognizes AOptix Technologies for its Pioneering Contribution to Security through Noninvasive Biometrics 2Frost & Sullivan Recognizes AOptix Technologies for its Pioneering Contribution to Security through Noninvasive Biometrics 3Frost & Sullivan Recognizes AOptix Technologies for its Pioneering Contribution to Security through Noninvasive Biometrics 4
HIV Reverse Transcriptase provides an excellent target for evaluating antiviral agents or catalyzing error prone synthesis on RNA and DNA templates....
OmniSlide thermal Cycler for slide applications. 20 slide capacity. Humidity Chamber. Slide Rack can be transferred directly to Wash Module to avoid handling individual slides....
HyPro 20 system for slide hybridization. 20 slide capacity. Active vibration system, slide rack and humidity chamber. Ideal for microarray and in situ hybridization....
... are cytopathic effect inhibition assays, also known as ... tissue culture supernatents; serum from PK studies and ... is defined as the quantity of interferon required ... viral infection by 50%. All standards ...
Biology Products: